Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

ABSTRACT: Prostate cancer is screened by testing circulating levels of the prostate-specific antigen (PSA) biomarker, monitoring changes over time, or a digital rectal exam. Abnormal results often lead to prostate biopsy. Prostate cancer positive patients are stratified into very low-risk, low-risk, intermediate-risk, and high-risk, based on clinical classification parameters, to assess therapy options. However, there remains a gap in our knowledge and a compelling need for improved risk stratification to inform clinical decisions and reduce both over-diagnosis and over-treatment. Further, current strategies for clinical intervention do not distinguish clinically aggressive prostate cancer from indolent disease. This mini-review takes advantage of a large number of functionally characterized microRN

SUBMITTER: Farina NH 

PROVIDER: S-EPMC5993634 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature